

10/521 998

DT rec'd PCT/PTO 18 JAN 2005

"Express Mail" mailing label number EL 832954748 US

Date of Deposit Jan. 18, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Arlington, VA 22202.

QUEEN THOMAS

Printed Name

Queen Thomas

Signature

X2

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Hinklin, *et al.* )  
  )  
  )  
National Phase )  
of PCT Serial No. : PCT/US2003/019561 )  
  )  
  )  
International )  
Filing Date: July 18, 2003 )  
  )  
  )  
For: PENTACYCLIC OXEPINES AND )  
  )  
  )  
  )  
  )  
Docket No.: X-15583 )

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

10/521 998

5 Rec'd PCT/PTO 18 JAN 2005

Serial No. PCT/US2003/019561

-2-

Applicants request consideration of this information.

Respectfully submitted,



Gilbert T. Voy  
Attorney for Applicant  
Registration No. 43,972  
Phone: 317-276-2966

Eli Lilly and Company  
Patent Division/GTV  
Lilly Corporate Center  
Indianapolis, Indiana 46285

January 12, 2005

FORM PTO 1449 (modified)	Atty. Docket No. X-15583	Serial No. <b>10/521 998</b>
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Hinklin, et al.	
	Filing Date	Group

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US			
	AB	US			
	AC	US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	EP 0 761669	09/02/1996			
	BB	EP 0 943329	03/01/1999			
	BC					
	BD					
	BP					
	BQ					
	BR					

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	GRESE, et al., Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues: Highly Potent Selective Estrogen Receptor Modulators, <i>J. Med. Chem.</i> , 1998, vol. 41, pp 1272-1283	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.